P1264: HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY

Lignende værker

• Serum proteome modulations upon treatment provides biological insight on response to treatment in relapsed mantle cell lymphoma
  af: Lavanya Lokhande, et al.
  Udgivet: (2022-07-01)
• Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
  af: Alexandra Albertsson-Lindblad, et al.
  Udgivet: (2019-08-01)
• Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors
  af: Anna Sandström Gerdtsson, et al.
  Udgivet: (2022-12-01)
• P1264: HEMATOPOIETIC CLONES WITH TP53 MUTATIONS EXPAND IN PATIENTS WITH MCL DURING LENALIDOMIDE-BASED THERAPY
  af: S. Husby, et al.
  Udgivet: (2022-06-01)
• MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and <i>TP53</i>/p53 – a Nordic Lymphoma Group study
  af: Joana M. Rodrigues, et al.
  Udgivet: (2023-08-01)